Table 1. Common Mechanisms of Drug-Drug Interactions MechanismDescriptionInteraction of DOACs With CYP450 Enzymes and Transporters ApixabanBetrixabanDabigatranEdoxabanRivaroxaban CYP450 enzymes 20%–25% metabolized by CYP3A4 <1% metabolized by CYP450 Not a substrate, inhibitor, or inducer of CYP450 enzym...
drug interactionsedoxabanP-glycoproteinpharmacokineticsAimsEdoxaban, a novel factor Xa inhibitor, is a substrate of cytochrome P450 3A4 (CYP3A4) and the efflux transporter P-glycoprotein (P-gp). Three edoxaban drug-drug interaction studies examined the effects of P-gp inhibitors with varying degrees...
respectively [35] with a decrease in the formation of active metabolites. Thus, statins with a lower likelihood of interactions need to be considered.
the effect of multiple drugs on DOAC exposure, and especially the impact of DDIs when concurring with drug–disease interactions as observed in renal impairment, has not been thoroughly elucidated [31]. In order to provide effective and safe anticoagulation...
Drug- Drug Interactions / Drug-Interactions / Drug-Drug Interaction (DDI) / Drug Interactions / Interaction drug (NOS) / Interaction / Drug interaction (NOS) / Drug interaction NOS / Drug interaction (finding) / Drug interaction (disorder) / Drug interaction with drug (finding) / Interactions...
Ritonavir, contained in NMV/r, is known to have significant drug-drug interactions (DDI) with several drugs frequently used by the elderly. This communication puts the problem with DDI with oral antiviral COVID-19 treatment into perspective by assessing the percentage of the elderly population at...
Valproate is the other of the two drugs that are known to cause major interactions with CBD. In addition to epilepsy, you can use valproic acid to treat some mental conditions and migraines. Valproic acid could cause severe, even life-threatening liver damage, usually within the first six mont...
Dabigatran is not a substrate, inhibitor, or inducer of hepatic CYPs [75]. As less than 4% of the active metabolite of edoxaban is metabolised by CYP3A4 [76], drug interactions with CYP inducers or inhibitors are not expected. However, rivaroxaban and apixaban are CYP3A4 substrates; co-...
has many of the characteristics required to address unmet clinical needs: high oral bioavailability, a fast onset/offset of action, dose-dependent pharmacokinetics and pharmacodynamics, few drug–drug or drug–food interactions and, as a result of these, no requirement for routine coagulation ...
Predicting quantitatively P-glycoprotein mediated drug-drug interactions and intestinal absorption using humanized mice 通过热力学和计算学的溶解度模型、GastroPlus软件预测、酮康唑皮下给药的细胞研究,来选择生物相容性溶剂 Biocompatible solvent selection based on thermodynamic and computational solubility models, in...